These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Design, synthesis and biological evaluation of cobalt(II)-Schiff base complexes as ATP-noncompetitive MEK1 inhibitors. Li H; Xi D; Niu Y; Wang C; Xu F; Liang L; Xu P J Inorg Biochem; 2019 Jun; 195():174-181. PubMed ID: 30954694 [TBL] [Abstract][Full Text] [Related]
63. Detection of allosteric kinase inhibitors by displacement of active site probes. Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235 [TBL] [Abstract][Full Text] [Related]
64. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells. Smutny T; Bitman M; Urban M; Dubecka M; Vrzal R; Dvorak Z; Pavek P Arch Toxicol; 2014 Dec; 88(12):2243-59. PubMed ID: 24819614 [TBL] [Abstract][Full Text] [Related]
65. Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors. Auld DS; Davis CA; Jimenez M; Knight S; Orme JP Assay Drug Dev Technol; 2015 Jun; 13(5):266-76. PubMed ID: 26107610 [TBL] [Abstract][Full Text] [Related]
66. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Wu PK; Park JI Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130 [TBL] [Abstract][Full Text] [Related]
67. MEK1/2 inhibitors in the treatment of gynecologic malignancies. Miller CR; Oliver KE; Farley JH Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059 [TBL] [Abstract][Full Text] [Related]
68. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations. Simard JR; Rauh D Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645 [TBL] [Abstract][Full Text] [Related]